7 completed, 3 terminated, 1 unknown. 5 Phase 1, 3 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Completed 2 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow KLH: new trials by email Literature Review of KLH trials Research Report on KLH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KLH Challenge to Explore the Human Immune Response Keyhole-Limpet Hemocyanin, Saline, Montanide ISA 51 VG - Immune Response | Not applicable | Unknown | University of Oxford | 39 | 2023-03-01 | 2023-05-25 |
| Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects ONO-4685, Placebo, KLH - Healthy Volunteers | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 78 | 2019-09-12 | 2024-05-03 |
| A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis 23-PPV, 13-PCV Booster, Influenza Vaccine - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Hoffmann-La Roche | 102 | 2015-10-27 | 2024-03-26 |
| Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects BMS-986090, Placebo matching with BMS-986090, Keyhole limpet hemocyanin - Healthy Adult Volunteers | Phase 1 | Terminated | Bristol-Myers Squibb | 130 | 2014-05-01 | 2016-05-12 |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 2 | Completed | Celldex Therapeutics | 127 | 2011-12-01 | 2020-02-17 |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH - Glioblastoma, Small Cell Glioblastoma | Phase 3 | Completed | Celldex Therapeutics | 745 | 2011-11-01 | 2018-01-16 |
| Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4 - Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL) | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2008-02-22 | 2017-04-12 |
| CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant keyhole limpet hemocyanin, tetanus toxoid - Germ Cell Tumor, Leukemia | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 19 | 2003-09-01 | 2017-11-29 |
| A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax) DT, Daclizumab, KLH - Kidney Transplantation | Phase 4 | Completed | Hoffmann-La Roche | 11 | 2003-04-01 | 2016-01-13 |
| S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer KLH, GMCSF - Brain Tumors, Gastric Cancer | Phase 1 | Terminated | SWOG Cancer Research Network | 14 | 2001-06-01 | 2015-03-06 |
| Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome Bacteriophage, rhuCD40L, KLH - Immunoproliferative Disorder | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 1999-10-01 | 2008-03-04 |
Brain Neoplasms (3) · Glioblastoma (2) · Gliosarcoma (2) · Leukemia (2) · Neoplasms (2) · Astrocytoma (1) · Carcinoma, Ovarian Epithelial (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Immunoproliferative Disorders (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
Celldex Therapeutics (2) · Hoffmann-La Roche (2) · Bristol-Myers Squibb (1) · Masonic Cancer Center, University of Minnesota (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Ono Pharmaceutical Co., Ltd. (1) · SWOG Cancer Research Network (1) · University of Oxford (1)
United States (9) · Canada (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Colombia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Israel (1)
James Fullerton, MBBS (1) · Junichiro Manako (1) · Marcie Tomblyn, MD, MS (1) · Robert B. Montgomery, MD (1) · Terry J Fry, M.D. (1)
PMID 26670466, PMID 28844499, PMID 32034072, PMID 32727835, PMID 36346112
2015 (1), R01CA082661 (1), U10CA032102 (1)